ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky

Aldeyra Therapeutics faces a securities class action lawsuit after the FDA rejected its lead drug candidate reproxalap, citing inconsistent and unreliable clinical trial data. ALDX stock plummeted 70.7% ($2.99 per share) on March 17, 2026. Investors who purchased shares between November 3, 2023 and March 16, 2026 may be eligible to participate in the class action, with the lead plaintiff application deadline set for May 29, 2026.